Shenzhenlubris Pharmaceuticals Co (SZSE:002294) 5-Year EBITDA Growth Rate : -7.50% (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co 5-Year EBITDA Growth Rate?

Shenzhenlubris Pharmaceuticals Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.21.

During the past 12 months, Shenzhenlubris Pharmaceuticals Co's average EBITDA Per Share Growth Rate was -9.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 41.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -7.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shenzhenlubris Pharmaceuticals Co was 69.20% per year. The lowest was -43.60% per year. And the median was 26.60% per year.

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's 5-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shenzhenlubris Pharmaceuticals Co's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's 5-Year EBITDA Growth Rate falls into.

Shenzhenlubris Pharmaceuticals Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Shenzhenlubris Pharmaceuticals Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines